Goldman Sachs: Maintains "Buy" rating on BILIBILI-W (09626) with a target price of HK$176.
Bilibili announced its first share buyback plan, which will repurchase $200 million worth of shares over the next two years.
Goldman Sachs released a research report, maintaining a "buy" rating on BILIBILI-W (09626) with an H-share target price of HK$176.
Goldman Sachs stated that Bilibili announced its first share repurchase plan, which will repurchase $200 million worth of stock in the next two years, demonstrating the company's healthy financial condition and ability to generate free cash flow.
The report mentioned that Bilibili achieved quarterly breakeven for the first time, with an adjusted operating profit of 272 million yuan in the third quarter, significantly higher than the bank's forecast by 31%, benefiting from marketing costs in line with expectations and well-controlled research and development expenses; revenue growth is in line with expectations.
Related Articles

New stock news | Jin Xun Group passed the hearing at the Hong Kong Stock Exchange and ranks fifth among China's cathode copper producers.

New Stock News | Jingfeng Medical has passed the hearing of the Hong Kong Stock Exchange and is committed to designing, developing, and manufacturing surgery Siasun Robot&Automation.
.png)
IPO news | Keen Gene submits application to Hong Kong Stock Exchange
New stock news | Jin Xun Group passed the hearing at the Hong Kong Stock Exchange and ranks fifth among China's cathode copper producers.

New Stock News | Jingfeng Medical has passed the hearing of the Hong Kong Stock Exchange and is committed to designing, developing, and manufacturing surgery Siasun Robot&Automation.

IPO news | Keen Gene submits application to Hong Kong Stock Exchange
.png)





